[{"address1": "500 Arsenal Street", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 607 0800", "fax": "617 607 0530", "website": "https://www.enanta.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 145, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay R. Luly Ph.D.", "age": 67, "title": "President, CEO & Director", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 1251859, "exercisedValue": 2025521, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul J. Mellett Jr.", "age": 68, "title": "Chief Financial & Administrative Officer", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 666844, "exercisedValue": 529982, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yat Sun Or Ph.D.", "age": 71, "title": "Senior VP of Research & Development and Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 729311, "exercisedValue": 424852, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathaniel S. Gardiner J.D.", "age": 69, "title": "Consultant", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 672675, "exercisedValue": 49136, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendan  Luu", "age": 48, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 622856, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Viera", "title": "Senior Director of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew P. Kowalsky J.D.", "age": 50, "title": "Chief Legal Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tara Lynn Kieffer Ph.D.", "age": 45, "title": "Chief Product Strategy Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 496852, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott T. Rottinghaus M.D.", "age": 49, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 616728, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 4, "compensationRisk": 7, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.86, "open": 6.16, "dayLow": 6.16, "dayHigh": 7.928, "regularMarketPreviousClose": 5.86, "regularMarketOpen": 6.16, "regularMarketDayLow": 6.16, "regularMarketDayHigh": 7.928, "beta": 0.568, "forwardPE": -1.4062508, "volume": 1996184, "regularMarketVolume": 1996184, "averageVolume": 530952, "averageVolume10days": 403100, "averageDailyVolume10Day": 403100, "bid": 7.44, "ask": 7.53, "bidSize": 100, "askSize": 100, "marketCap": 159993744, "fiftyTwoWeekLow": 4.71, "fiftyTwoWeekHigh": 17.8, "priceToSalesTrailing12Months": 2.2233706, "fiftyDayAverage": 5.9928, "twoHundredDayAverage": 10.784625, "currency": "USD", "enterpriseValue": 186998032, "profitMargins": -1.6026801, "floatShares": 15438417, "sharesOutstanding": 21332500, "sharesShort": 3440099, "sharesShortPriorMonth": 2985735, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.16239999, "heldPercentInsiders": 0.060900003, "heldPercentInstitutions": 1.00662, "shortRatio": 20.91, "shortPercentOfFloat": 0.1726, "impliedSharesOutstanding": 21332500, "bookValue": 7.03, "priceToBook": 1.0668563, "lastFiscalYearEnd": 1696032000, "nextFiscalYearEnd": 1727654400, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -115329000, "trailingEps": -4.95, "forwardEps": -4.82, "enterpriseToRevenue": 2.599, "enterpriseToEbitda": -1.554, "52WeekChange": -0.5488838, "SandP52WeekChange": 0.20904708, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ENTA", "underlyingSymbol": "ENTA", "shortName": "Enanta Pharmaceuticals, Inc.", "longName": "Enanta Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1363872600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "0716474a-69e6-3365-b278-ac9fe128aaa5", "messageBoardId": "finmb_345286", "gmtOffSetMilliseconds": -18000000, "currentPrice": 7.5, "targetHighPrice": 21.0, "targetLowPrice": 5.0, "targetMeanPrice": 15.42857, "targetMedianPrice": 18.0, "recommendationMean": 2.28571, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 230084992, "totalCashPerShare": 10.859, "ebitda": -120341000, "totalDebt": 226174000, "quickRatio": 4.649, "currentRatio": 4.922, "totalRevenue": 71960000, "debtToEquity": 151.881, "revenuePerShare": 3.407, "returnOnAssets": -0.1718, "returnOnEquity": -0.59643, "grossProfits": 71960000, "freeCashflow": -63273624, "operatingCashflow": -89966000, "revenueGrowth": -0.049, "grossMargins": 1.0, "ebitdaMargins": -1.67233, "operatingMargins": -1.34578, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-14"}]